secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001193125-26-191487
Event type: earnings
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled
--------------------------------------------------------------------------------

- Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.
- Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.
- Maintenance dosing study for VK2735 is ongoing with data expected in 3Q26; the study explores weekly, every-other-week, and monthly dosing.
- IND filed for novel amylin agonist VK3019; Phase 1 trial initiation planned for 2Q26.
- First quarter 2026 cash position was $603 million, with R&D expenses of $150.2 million and net loss of $158.3 million, compared to $45.6 million net loss in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-191487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer